Estrogen promotes resistance to bevacizumab in murine models of non-small cell lung cancer.
暂无分享,去创建一个
Jing Wang | J. Minna | I. Wistuba | J. Heymach | H. Tran | L. Diao | X. Le | M. H. Herynk | T. Cascone | M. Nilsson | S. Ramachandran | B. Saigal | Sonia Patel | Sonia A Patel | J. Heymach
[1] R. Gray,et al. Sex Differences in Outcome with Bevacizumab Therapy: Analysis of Patients with Advanced-Stage Non-small Cell Lung Cancer Treated with or without Bevacizumab in Combination with Paclitaxel and Carboplatin in the Eastern Cooperative Oncology Group Trial 4599 , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[2] D. Heitjan,et al. Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells. , 1995, The Journal of clinical endocrinology and metabolism.
[3] C. Murdoch,et al. Neutrophil-mediated tumour angiogenesis: subversion of immune responses to promote tumour growth. , 2013, Seminars in cancer biology.
[4] T. Oyama,et al. Association between estrogen receptor-beta expression and epidermal growth factor receptor mutation in the postoperative prognosis of adenocarcinoma of the lung. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] J. Folkman,et al. Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. , 1991, The New England journal of medicine.
[6] G. Mills,et al. An Integrated Molecular Analysis of Lung Adenocarcinomas Identifies Potential Therapeutic Targets among TTF1-Negative Tumors, Including DNA Repair Proteins and Nrf2 , 2015, Clinical Cancer Research.
[7] I. Wistuba,et al. Aromatase expression predicts survival in women with early-stage non small cell lung cancer. , 2007, Cancer research.
[8] R. Johnson,et al. A role for VEGF as a negative regulator of pericyte function and vessel maturation. , 2008, Nature.
[9] Hideki Kawai,et al. Estrogen Receptor α and β are Prognostic Factors in Non–Small Cell Lung Cancer , 2005, Clinical Cancer Research.
[10] H. Schnaper,et al. Estrogen promotes angiogenic activity in human umbilical vein endothelial cells in vitro and in a murine model. , 1995, Circulation.
[11] T. Larson,et al. Phase II Study of Biweekly Carboplatin, Gemcitabine, and Bevacizumab as First-line Treatment in Patients with Stage IIIB/IV NSCLC , 2014, American journal of clinical oncology.
[12] Markus Kipp,et al. Combined Application of 17β-Estradiol and Progesterone Enhance Vascular Endothelial Growth Factor and Surfactant Protein Expression in Cultured Embryonic Lung Cells of Mice , 2009, International journal of pediatrics.
[13] D. Hanahan,et al. Pericytes promote endothelial cell survival through induction of autocrine VEGF-A signaling and Bcl-w expression. , 2011, Blood.
[14] Gordon C Jayson,et al. Antiangiogenic therapy in oncology: current status and future directions , 2016, The Lancet.
[15] B. Fingleton,et al. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. , 2004, Cancer cell.
[16] Bevacizumab for the treatment of non-small cell lung cancer patients with synchronous brain metastases , 2019, Scientific Reports.
[17] R. Herbst,et al. Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinoma. , 2011, The Journal of clinical investigation.
[18] J. Luketich,et al. Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor alpha and beta and show biological responses to estrogen. , 2002, Cancer research.
[19] E. Baldini,et al. Women and lung cancer. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[20] R. Kishore,et al. 17Beta-estradiol mobilizes bone marrow-derived endothelial progenitor cells to tumors. , 2008, Cancer research.
[21] A. Miller,et al. Are female smokers at higher risk for lung cancer than male smokers? A case-control analysis by histologic type. , 1993, American journal of epidemiology.
[22] M. Fishbein,et al. Aromatase inhibitors in human lung cancer therapy. , 2005, Cancer research.
[23] J. Siegfried,et al. Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects. , 2005, Cancer research.
[24] A. Jemal,et al. Cancer statistics, 2020 , 2020, CA: a cancer journal for clinicians.
[25] M. J. Jarzynka,et al. Estradiol and nicotine exposure enhances A549 bronchioloalveolar carcinoma xenograft growth in mice through the stimulation of angiogenesis. , 2006, International journal of oncology.
[26] D. Hanahan,et al. Functions of Paracrine PDGF Signaling in the Proangiogenic Tumor Stroma Revealed by Pharmacological Targeting , 2008, PLoS medicine.
[27] M. Fishbein,et al. Estrogen receptor signaling pathways in human non-small cell lung cancer , 2007, Steroids.
[28] L. Holmberg,et al. Lung cancer incidence in never smokers. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] O. Miettinen,et al. Women's susceptibility to tobacco carcinogens and survival after diagnosis of lung cancer. , 2006, JAMA.
[30] Xianglin L. Du,et al. Menopausal Hormone Therapy and Lung Cancer-Specific Mortality Following Diagnosis: The California Teachers Study , 2014, PloS one.
[31] E. Keshet,et al. A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. , 1998, Development.
[32] A. Potti,et al. Hormone replacement therapy is associated with decreased survival in women with lung cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] Zhuo Wang,et al. Estrogen receptors promote NSCLC progression by modulating the membrane receptor signaling network: a systems biology perspective , 2019, Journal of Translational Medicine.
[34] L. Bubendorf,et al. Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: a multicenter phase II trial (SAKK 19/05). , 2012, Lung cancer.
[35] O. Arrieta,et al. Influence of estrogen in non-small cell lung cancer and its clinical implications. , 2018, Journal of thoracic disease.
[36] Steven Song,et al. The role of pericytes in blood-vessel formation and maintenance. , 2005, Neuro-oncology.
[37] Federico Cappuzzo,et al. Atezolizumab for First‐Line Treatment of Metastatic Nonsquamous NSCLC , 2018, The New England journal of medicine.
[38] A R Dunn,et al. Mice lacking granulocyte colony-stimulating factor have chronic neutropenia, granulocyte and macrophage progenitor cell deficiency, and impaired neutrophil mobilization. , 1994, Blood.
[39] G. Blumenschein,et al. Angiogenesis Inhibitors for Lung Cancer: Clinical Developments and Future Directions , 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[40] J. Dering,et al. Antiestrogen Fulvestrant Enhances the Antiproliferative Effects of Epidermal Growth Factor Receptor Inhibitors in Human Non–Small-Cell Lung Cancer , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[41] N. Ferrara,et al. The biology of VEGF and its receptors , 2003, Nature Medicine.
[42] J. Manson,et al. Lung cancer among postmenopausal women treated with estrogen alone in the women's health initiative randomized trial. , 2010, Journal of the National Cancer Institute.
[43] J. Minna,et al. Epidermal growth factor receptor regulates MET levels and invasiveness through hypoxia-inducible factor-1α in non-small cell lung cancer cells , 2010, Oncogene.
[44] J. Siegfried,et al. Combining the Multitargeted Tyrosine Kinase Inhibitor Vandetanib with the Antiestrogen Fulvestrant Enhances Its Antitumor Effect in Non-small Cell Lung Cancer , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[45] Patricia A. Young,et al. Randomized phase II study of fulvestrant and erlotinib compared with erlotinib alone in patients with advanced or metastatic non-small cell lung cancer. , 2018, Lung cancer.
[46] R. DuBois,et al. CXCL1 Is Critical for Premetastatic Niche Formation and Metastasis in Colorectal Cancer. , 2017, Cancer research.
[47] B. Li,et al. Gender Differences in Low-Molecular-Mass-Induced Acute Lung Inflammation in Mice , 2021, International journal of molecular sciences.
[48] Y. Meng,et al. G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models , 2009, Proceedings of the National Academy of Sciences.
[49] T. Bruno,et al. Influence of Estrogen on the NSCLC Microenvironment: A Comprehensive Picture and Clinical Implications , 2020, Frontiers in Oncology.
[50] I. Wistuba,et al. Immunohistochemical Expression of Estrogen and Progesterone Receptors Identifies a Subset of NSCLCs and Correlates with EGFR Mutation , 2009, Clinical Cancer Research.
[51] L. Striker,et al. Female gender, estrogen loss, and Sub-RPE deposit formation in aged mice. , 2003, Investigative ophthalmology & visual science.
[52] Kathleen A Cronin,et al. Annual Report to the Nation on the Status of Cancer, part I: National cancer statistics , 2018, Cancer.
[53] Michael C. Schmid,et al. Myeloid cell trafficking and tumor angiogenesis. , 2007, Cancer letters.
[54] L. Ellis,et al. Pathways Mediating Resistance to Vascular Endothelial Growth Factor–Targeted Therapy , 2008, Clinical Cancer Research.
[55] W. McGuire,et al. Induction of the estrogen-regulated "24K" protein by heat shock. , 1989, Cancer research.
[56] J. Siegfried,et al. Preclinical Evidence for Combined Use of Aromatase Inhibitors and NSAIDs as Preventive Agents of Tobacco‐Induced Lung Cancer , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[57] D. Hanahan,et al. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. , 2003, The Journal of clinical investigation.
[58] U. Landegren,et al. Endothelial PDGF-B retention is required for proper investment of pericytes in the microvessel wall. , 2003, Genes & development.